The healthcare landscape of 2026 is moving fast, and the latest “On Background” special session didn’t pull any punches. Host Stephen Parente sat down with policy heavyweights Doug Holtz-Eakin (Former CBO Director), Marta Wosinska (Brookings Institution), and Rena Conti (Boston University) to dissect a year defined by massive innovation and equally massive uncertainty.
Since you likely missed the live session with the students in their healthcare marketplace class, here are the key takeaways from a conversation that ranged from “pirate patches” to the federal budget.
The Good: Innovation and Competition are Winning
Despite the “eye-rolling” from the panel when asked what’s working, the experts highlighted significant success stories that often get lost in the noise of political debates.
- The Generic Triumph: The panel emphasized a frequently overlooked fact: the U.S. has a highly efficient “price control” that works through the market. Over 90% of U.S. prescriptions are generics. Both Holtz-Eakin and Wosinska highlighted that the U.S. actually pays significantly less for generic drugs than Europeans do—a major win for market efficiency.
- The Biosimilar Boom: Rena Conti noted that competition is finally working. Biosimilars are hitting the market with 50% price drops and significant market share, proving that the decade-long wait for biological competition is over.
- The “Miracle” Pipeline: From the first new schizophrenia treatment in 20 years to revolutionary HIV prevention and in-vivo gene therapies, the panel agreed that medical innovation remains the “bright spot” of the U.S. system.
- GLP-1s: Marta Wosinska highlighted the transformational impact of weight-loss drugs, which are not only changing health outcomes but also seeing incredible market competition.
The Bad: Price Controls and the “Wild West” of Insurance
The optimism shifted to concern when discussing how to pay for these breakthroughs without breaking the system.
- The MFN Skepticism: The group expressed deep skepticism toward “Most Favored Nation” (MFN) pricing—the idea that the U.S. should pay the same lower prices as other countries.
- The “Price Floor” Risk: Marta Wosinska warned that because the U.S. is the world’s largest market, forcing manufacturers to match lower foreign prices might backfire. Instead of lowering U.S. prices, manufacturers might simply raise prices in smaller countries.
- Fairness vs. Savings: There is a fundamental tension here. While MFN might achieve “fairness” by making Europeans pay more, it doesn’t necessarily mean Americans will pay less.
- Subsidies in Chaos: Doug Holtz-Eakin described the current insurance subsidy landscape as the “Wild West,” calling for an “adult conversation” to rationalize how we fund premiums.
- The Medicaid Cliff: Rena Conti expressed concern over people dropping off Medicaid rolls, creating a “vicious cycle” of uninsurance.
The Hopeful: Markets and Transparency
Is there a path forward? The panel found common ground in the shift toward economic reality.
- Price Transparency: New tools are allowing employers and consumers to “shop” for care, which the panel hopes will eventually rationalize the marketplace.
- Economics 101: Doug Holtz-Eakin noted a refreshing change in mindset: the recognition that health policy is economic policy. The era of believing Washington can dictate outcomes without market incentives seems to be fading.
- Drug Shortages: Policymakers are finally acknowledging that shortages are driven by economic incentives, not just manufacturing glitches.
The Speed Round: AI and “TrumpRx”
The episode wrapped with a quick look at the latest buzzwords:
- AI (Fact or Fiction?): The verdict? Not ready for prime time. While there is hope for AI to break the physician-only model of care, the panel warned of “garbage in, garbage out” data and regulatory landmines.
- TrumpRx: The panel clarified a common misconception. TrumpRx is often more about access than just price. For drugs not covered by insurance (like certain GLP-1s or fertility drugs), it’s a win. However, for those in high-deductible plans, buying outside their insurance could actually be “harmful” if it doesn’t count toward their deductible.
Final Word: The CBO “Blind Spot”
Doug Holtz-Eakin provided a sobering reminder of how legislation is actually “scored.” The Congressional Budget Office (CBO) focuses strictly on federal cash flows over a 10-year window. This “blind spot” means the long-term societal value and health benefits of a life-saving drug often don’t show up on the government’s balance sheet, making “good” policy look like “bad” math.
Listen to the full episode at Apple Podcasts or Spotify.